Observational studyBrain and behavior2026
Association of the TREM-1-STAT3 Axis With Stroke Severity and Functional Outcomes in Ischemic Stroke: A Prospective Case-Control Study.
Observational study in Brain and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundInformation regarding the signaling axis involving triggering receptor expressed on myeloid cells 1 (TREM-1) and its downstream mediator, signal transducer and activator of transcription 3 (STAT3), remains limited in ischemic stroke. We investigated the plasma levels of TREM-1 in patients with ischemic stroke and compared to controls. Second, we investigated the potential correlation between plasma TREM-1 levels and STAT3 expression in peripheral blood mononuclear cells (PBMCs) and explored their associations with stroke severity and functional outcomes.
methodsIn an observational case-control study, plasma and PBMCs from participants were collected to measure TREM-1 and STAT3 expression levels. The National Institutes of Health Stroke Scale (NIHSS) at admission, day 7, and 1 and 3 months, and the modified Rankin Scale (mRS) at 3 months post-discharge were assessed. Plasma TREM-1 levels and STAT3 expression were measured by enzyme-linked immunosorbent assay (ELISA) and quantitative reverse transcription polymerase chain reaction (RT-qPCR), respectively. The Inflammation-Related Principal Component Score (IRPCS) was examined for its association with 3-month functional outcome.
resultTREM-1 and STAT3 were significantly elevated in acute ischemic stroke (AIS) patients (p < 0.05, p < 0.0001) and positively correlated (ρ = 0.432, p < 0.0001). Both biomarkers correlated with the NIHSS at 1 and 3 months and mRS at 3 months (all p < 0.05). The composite IRPCS showed the strongest association with poor 3-month functional outcome among the tested biomarkers (OR = 2.84, 95% CI: 1.32-6.12, p = 0.008).
conclusionPlasma TREM-1 levels were positively correlated with STAT3 expression. The TREM-1-STAT3 axis was associated with stroke severity and 3-month functional outcome in AIS patients. These findings should be regarded as exploratory and require validation in larger cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.